Angelos M. Stergiou

CIK: 0001724253

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (60.0%)

Compensation grants

Other (G, F, J, C, D, …)2 (40.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

SLS

SELLAS Life Sciences Group, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

SLS
SELLAS Life Sciences Group, Inc.
Jun 16, 2026
Award(A)
Direct
1.1M shares-
SLS
SELLAS Life Sciences Group, Inc.
Dec 3, 2025
Other(J)
Direct
187.1K shares at avg. $1.50$281K
SLS
SELLAS Life Sciences Group, Inc.
Jan 10, 2025
Award(A)
Direct
257K shares-
SLS
SELLAS Life Sciences Group, Inc.
Jan 10, 2025
Award(A)
Direct
243.9K shares-
SLS
SELLAS Life Sciences Group, Inc.
Dec 4, 2024
Other(J)
Direct
28.3K shares at avg. $1.13$32K

		Type	Shares	Price		Ownership
Jun 16, 2026	SLS SELLAS Life Sciences Group, Inc.	Award(A)	1,065,000	-	$0	Direct
Dec 3, 2025	SLS SELLAS Life Sciences Group, Inc.	Other(J)	187,066	$1.50	$280,599	Direct
Jan 10, 2025	SLS SELLAS Life Sciences Group, Inc.	Award(A)	257,000	-	$0	Direct
Jan 10, 2025	SLS SELLAS Life Sciences Group, Inc.	Award(A)	243,900	-	$0	Direct
Dec 4, 2024	SLS SELLAS Life Sciences Group, Inc.	Other(J)	28,289	$1.13	$31,967	Direct

1-5 of 5 transactions

About Stergiou Angelos M.

Stergiou Angelos M. (SEC CIK 0001724253) files insider reports with the SEC as President and CEO of SELLAS Life Sciences Group, Inc. (SLS).

Signal8 holds 4 ownership filings by Stergiou Angelos M., all Form 4s, filed between Dec 5, 2024 and Jun 18, 2026. Those filings report 5 transactions, from Dec 4, 2024 to Jun 16, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Stergiou Angelos M.'s filings is in NEW YORK, NY.

Recent filings by Stergiou Angelos M.

Jun 16, 2026: Grant or award of SLS shares (Form 4, code A).
Dec 3, 2025: Other transaction of SLS shares (Form 4, code J).
Jan 10, 2025: Grants or awards of SLS shares (2 lines, Form 4, code A).
Dec 4, 2024: Other transaction of SLS shares (Form 4, code J).

Other insiders filing for SELLAS Life Sciences Group, Inc. (SLS)

Varian John, Director
VAN NOSTRAND ROBERT L, Director
SCHEINBERG DAVID A, Director
CICIC DRAGAN, SVP, Chief Development Officer
Burns John Thomas, CFO
Kalin Katherine Bach, Director

How to read Form 4 transaction codes